XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

Diabetes Care

Volumn 27, Issue 1, 2004, Pages 155-161

  Torgerson, Jarl S ^a   Hauptman, Jonathan ^b   Boldrin, Mark N ^a   Sjöström, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC RESTRICTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; DIABETES MELLITUS; DOUBLE-BLIND METHOD; ENERGY INTAKE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; LACTONES; LIFE STYLE; LIPASE; MALE; MIDDLE AGED; OBESITY; PLACEBOS; PROSPECTIVE STUDIES;

EID: 1042303480     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.1.155     Document Type: Article

References (22)

1. World Health Organization: Controlling the global obesity epidemic [article online], 2002. Available from http://www. who.int/nut/obs.htm. Accessed 26 March 2003
2. Colditz GA, Willett WC, Rotnitzky A, Manson JE: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122:481-486, 1995
3. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH: The disease burden associated with overweight and obesity. JAMA 282:1523-1529, 1999
4. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345:790-797, 2001
5. Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ: Obesity prevention: the case for action. Int J Obes Relat Metab Disord 26:425-436, 2002
6. Sjöström CD, Peltonen M, Wedel H, Sjöström L: Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 36:20-25, 2000
7. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Klukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
8. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
9. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjöström L: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 160:1321-1326, 2000
10. Torgerson JS, Arlinger K, Käppi M, Sjöström L: Principles for enhanced recruitment of subjects in a large clinical trial: the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. Control Clin Trials 22:515-525, 2001
11. World Health Organization: Prevention of Diabetes Mellitus. Geneva, World Health Org., 1994, p. 17-18 (Tech. Rep. Ser., no. 844)
12. Lindroos AK, Lissner L, Sjöström L: Validity and reproducibility of a self-administered dietary questionnaire in obese and non-obese subjects. Eur J Clin Nutr 47:461-481, 1993
13. Ware JH: Interpreting incomplete data in studies of diet and weight loss. N Engl J Med 348:2136-2137, 2003
14. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352:167-172, 1998
15. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281:235-242, 1999
16. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G: Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years' treatment with orlistat for obesity: European Orlistat Obesity Study Group. Obes Res 8:49-61, 2000
17. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
18. Eriksson KF, Lindgärde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmö feasibility study. Diabetologia 34:891-898, 1991
19. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
20. Buchanan T, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002
21. Safer DJ: Diet, behavior modification and exercise: a review of obesity treatments from a longitudinal perspective. South Med J 84:1470-1474, 1991
22. Glenny AM, O'Meara S, Melville A, Sheldon TA, Wilson C: The treatment and prevention of obesity: a systematic review of the literature. Int J Obes Relat Metab Disord 21:715-737, 1997